alanine has been researched along with Parkinsonian Disorders in 12 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Safinamide is an α-aminoamide derivative that is currently in Phase III clinical trial development as an add-on therapy to levodopa or dopamine agonists for patients with Parkinson's disease." | 5.39 | Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. ( Collins-Praino, LE; Lobianco, C; Podurgiel, S; Randall, PA; Roach, A; Salamone, JD; Yohn, S, 2013) |
| "To study parkinsonism, dementia, dystonia, and amyotrophy as subphenotypes of SCA2, and to explore the effect of CAG repeats at different loci and of mitochondrial polymorphism A10398G as modifiers of phenotype." | 1.46 | Neurological phenotypes in spinocerebellar ataxia type 2: Role of mitochondrial polymorphism A10398G and other risk factors. ( Augustin, MC; Barsottini, O; Jardim, LB; Locks-Coelho, LD; Monte, TL; Pedroso, JL; Pereira, FS; Reckziegel, EDR; Santos, ASP; Saraiva-Pereira, ML; Vargas, FR, 2017) |
| "Safinamide or vehicle was delivered from days 0 or 1, for 7 days, via sub-cutaneous mini-pumps." | 1.43 | Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease. ( Mullali, G; Piers, T; Pocock, JM; Roach, A; Sadeghian, M; Smith, KJ, 2016) |
| "Safinamide pre-treatment (3, 10, 20 and 30 mg/kg) dose-dependently reduced LID scores, in two acute and one semi-chronic experiment." | 1.39 | Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. ( Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M, 2013) |
| "Safinamide is an α-aminoamide derivative that is currently in Phase III clinical trial development as an add-on therapy to levodopa or dopamine agonists for patients with Parkinson's disease." | 1.39 | Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. ( Collins-Praino, LE; Lobianco, C; Podurgiel, S; Randall, PA; Roach, A; Salamone, JD; Yohn, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stayte, S | 1 |
| Laloli, KJ | 1 |
| Rentsch, P | 1 |
| Lowth, A | 1 |
| Li, KM | 1 |
| Pickford, R | 1 |
| Vissel, B | 1 |
| Pisanò, CA | 1 |
| Brugnoli, A | 1 |
| Novello, S | 1 |
| Caccia, C | 2 |
| Keywood, C | 2 |
| Melloni, E | 2 |
| Vailati, S | 2 |
| Padoani, G | 2 |
| Morari, M | 1 |
| Sciaccaluga, M | 1 |
| Mazzocchetti, P | 1 |
| Bastioli, G | 1 |
| Ghiglieri, V | 1 |
| Cardinale, A | 1 |
| Mosci, P | 1 |
| Picconi, B | 1 |
| Calabresi, P | 1 |
| Tozzi, A | 1 |
| Monte, TL | 1 |
| Pereira, FS | 1 |
| Reckziegel, EDR | 1 |
| Augustin, MC | 1 |
| Locks-Coelho, LD | 1 |
| Santos, ASP | 1 |
| Pedroso, JL | 1 |
| Barsottini, O | 1 |
| Vargas, FR | 1 |
| Saraiva-Pereira, ML | 1 |
| Jardim, LB | 1 |
| Mishra, A | 1 |
| Krishnamurthy, S | 1 |
| Grégoire, L | 1 |
| Jourdain, VA | 1 |
| Townsend, M | 1 |
| Roach, A | 3 |
| Di Paolo, T | 1 |
| Sadeghian, M | 1 |
| Mullali, G | 1 |
| Pocock, JM | 1 |
| Piers, T | 1 |
| Smith, KJ | 1 |
| Podurgiel, S | 1 |
| Collins-Praino, LE | 1 |
| Yohn, S | 1 |
| Randall, PA | 1 |
| Lobianco, C | 1 |
| Salamone, JD | 1 |
| Hope, AD | 1 |
| Myhre, R | 1 |
| Kachergus, J | 1 |
| Lincoln, S | 1 |
| Bisceglio, G | 1 |
| Hulihan, M | 1 |
| Farrer, MJ | 1 |
| Jimenez-Escrig, A | 1 |
| Rabano, A | 1 |
| Guerrero, C | 1 |
| Simon, J | 1 |
| Barquero, MS | 1 |
| Güell, I | 1 |
| Ginestal, RC | 1 |
| Montero, T | 1 |
| Orensanz, L | 1 |
| Leutenegger, AL | 1 |
| Salih, MA | 1 |
| Ibáñez, P | 1 |
| Mukhtar, MM | 1 |
| Lesage, S | 1 |
| Arabi, A | 1 |
| Lohmann, E | 1 |
| Dürr, A | 1 |
| Ahmed, AE | 1 |
| Brice, A | 1 |
| Krüger, R | 1 |
| Kuhn, W | 1 |
| Leenders, KL | 1 |
| Sprengelmeyer, R | 1 |
| Müller, T | 1 |
| Woitalla, D | 1 |
| Portman, AT | 1 |
| Maguire, RP | 1 |
| Veenma, L | 1 |
| Schröder, U | 1 |
| Schöls, L | 1 |
| Epplen, JT | 1 |
| Riess, O | 1 |
| Przuntek, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Parkin Mutations and Their Functional Consequences[NCT00136721] | 2,500 participants | Observational | 2002-06-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for alanine and Parkinsonian Disorders
| Article | Year |
|---|---|
The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain.
Topics: Alanine; Animals; Dopaminergic Neurons; GluK2 Kainate Receptor; GluK3 Kainate Receptor; Mesencephalo | 2020 |
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Oxidopamine; | 2020 |
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, D | 2020 |
Neurological phenotypes in spinocerebellar ataxia type 2: Role of mitochondrial polymorphism A10398G and other risk factors.
Topics: Adult; Aged; Alanine; Ataxin-2; Dementia; Dystonia; Female; Genetic Predisposition to Disease; Glyci | 2017 |
Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with α-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson's Model in Rats.
Topics: Administration, Oral; Alanine; alpha-Synuclein; Animals; Antioxidants; Antiparkinson Agents; Apoptos | 2019 |
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergi | 2013 |
Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Dopaminergic Neurons; Male; Microglia; Nerve Degeneration; Neuroprot | 2016 |
Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Locomotion; Male; Muscarini | 2013 |
Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease.
Topics: Adult; Age Factors; Alanine; alpha-Synuclein; DNA Mutational Analysis; Exons; Family Health; Female; | 2004 |
New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism.
Topics: Adult; Alanine; Amyloid beta-Peptides; Brain; Dementia; DNA Mutational Analysis; Family Health; Fema | 2004 |
Juvenile-onset Parkinsonism as a result of the first mutation in the adenosine triphosphate orientation domain of PINK1.
Topics: Adenosine Triphosphate; Adolescent; Adult; Age of Onset; Alanine; Amino Acid Sequence; Aspartic Acid | 2006 |
Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers.
Topics: Aged; Alanine; alpha-Synuclein; Amino Acid Sequence; Apolipoproteins E; Brain; DNA Mutational Analys | 2001 |